Zacks Investment Research upgraded shares of Nanobiotix (NASDAQ:NBTX – Get Rating) from a hold rating to a buy rating in a research note published on Saturday, Zacks.com reports. Zacks Investment Research currently has $5.50 target price on the stock.
According to Zacks, “Nanobiotix S.A. is a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer. The company’s proprietary technology includes NBTXR3. Nanobiotix S.A. is headquartered in Paris, France. “
NBTX opened at $5.32 on Friday. Nanobiotix has a 12-month low of $4.65 and a 12-month high of $18.00. The firm has a 50 day moving average of $6.28 and a two-hundred day moving average of $7.47.
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Further Reading
- Get a free copy of the StockNews.com research report on Nanobiotix (NBTX)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Get a free copy of the Zacks research report on Nanobiotix (NBTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
